Patents by Inventor Tacey X. Viegas

Tacey X. Viegas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190099363
    Abstract: Methods of modifying the rate of systemic absorption of a drug administered to a subject by a pulmonary route, the method comprising covalently conjugating a hydrophilic polymer to a drug, wherein the drug has a half-life of elimination from the lung of less than about 180 minutes, to form a drug-polymer conjugate, wherein the drug-polymer conjugate has a net hydrophilic character and a weight average molecular weight of from about 50 to about 20,000 Daltons, and wherein the half-life of elimination from the lung of the drug-polymer conjugate is at least about 1.5-fold greater than the half-life of elimination from the lung of the drug, wherein the half-life of elimination from the lung is measured by bronchioalveolar lavage followed by assaying residual lung material.
    Type: Application
    Filed: June 27, 2018
    Publication date: April 4, 2019
    Inventors: C. Simone Fishburn, David Lechuga-Ballesteros, Tacey X. Viegas, Mei-Chang Kuo, Hema Gursahani, Chester Leach, Yuan Song
  • Publication number: 20180021444
    Abstract: Provided herein are water-soluble prodrugs, compositions comprising such prodrugs, and related methods of making and administering the same. The prodrugs of the invention comprise a water-soluble polymer having three or more arms, at least three of which are typically covalently attached to an active agent, e.g., a small molecule. The conjugates of the invention provide an optimal balance of polymer size and structure for achieving improved drug loading, since the conjugates of the invention possess three or more active agents releasably attached to a multi-armed water-soluble polymer. The prodrugs of the invention are therapeutically effective, and exhibit improved properties in-vivo when compared to unmodified parent drug.
    Type: Application
    Filed: October 3, 2017
    Publication date: January 25, 2018
    Inventors: Xuan Zhao, Michael D. Bentley, Zhongxu Ren, Tacey X. Viegas
  • Patent number: 9808533
    Abstract: Provided herein are water-soluble prodrugs, compositions comprising such prodrugs, and related methods of making and administering the same. The prodrugs of the invention comprise a water-soluble polymer having three or more arms, at least three of which are typically covalently attached to an active agent, e.g., a small molecule. The conjugates of the invention provide an optimal balance of polymer size and structure for achieving improved drug loading, since the conjugates of the invention possess three or more active agents releasably attached to a multi-armed water-soluble polymer. The prodrugs of the invention are therapeutically effective, and exhibit improved properties in-vivo when compared to unmodified parent drug.
    Type: Grant
    Filed: May 2, 2016
    Date of Patent: November 7, 2017
    Assignee: Nektar Therapeutics
    Inventors: Xuan Zhao, Michael David Bentley, Zhongxu Ren, Tacey X. Viegas
  • Publication number: 20170095565
    Abstract: Methods of modifying the rate of systemic absorption of a drug administered to a subject by a pulmonary route, the method comprising covalently conjugating a hydrophilic polymer to a drug, wherein the drug has a half-life of elimination from the lung of less than about 180 minutes, to form a drug-polymer conjugate, wherein the drug-polymer conjugate has a net hydrophilic character and a weight average molecular weight of from about 50 to about 20,000 Daltons, and wherein the half-life of elimination from the lung of the drug-polymer conjugate is at least about 1.5-fold greater than the half-life of elimination from the lung of the drug, wherein the half-life of elimination from the lung is measured by bronchoalveolar lavage followed by assaying residual lung material.
    Type: Application
    Filed: June 9, 2016
    Publication date: April 6, 2017
    Inventors: Michael D. Bentley, Tacey X. Viegas, Richard R. Goodin, Lin Cheng, Xuan Zhao
  • Publication number: 20170056514
    Abstract: Provided herein are water-soluble prodrugs, compositions comprising such prodrugs, and related methods of making and administering the same. The prodrugs of the invention comprise a water-soluble polymer having three or more arms, at least three of which are typically covalently attached to an active agent, e.g., a small molecule. The conjugates of the invention provide an optimal balance of polymer size and structure for achieving improved drug loading, since the conjugates of the invention possess three or more active agents releasably attached to a multi-armed water-soluble polymer. The prodrugs of the invention are therapeutically effective, and exhibit improved properties in-vivo when compared to unmodified parent drug.
    Type: Application
    Filed: May 2, 2016
    Publication date: March 2, 2017
    Inventors: Xuan Zhao, Michael David Bentley, Zhongxu Ren, Tacey X. Viegas
  • Patent number: 9388104
    Abstract: Provided are methods of preparing a monodisperse oligo (ethylene glycol) reagent composition.
    Type: Grant
    Filed: April 8, 2014
    Date of Patent: July 12, 2016
    Assignee: Nektar Therapeutics
    Inventors: Michael D. Bentley, Tacey X. Viegas, Richard R. Goodin, Lin Cheng, Xuan Zhao
  • Patent number: 9333200
    Abstract: Provided herein are water-soluble prodrugs, compositions comprising such prodrugs, and related methods of making and administering the same. The prodrugs of the invention comprise a water-soluble polymer having three or more arms, at least three of which are typically covalently attached to an active agent, e.g., a small molecule. The conjugates of the invention provide an optimal balance of polymer size and structure for achieving improved drug loading, since the conjugates of the invention possess three or more active agents releasably attached to a multi-armed water-soluble polymer. The prodrugs of the invention are therapeutically effective, and exhibit improved properties in-vivo when compared to unmodified parent drug.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: May 10, 2016
    Assignee: Nektar Therapeutics
    Inventors: Xuan Zhao, Michael David Bentley, Zhongxu Ren, Tacey X. Viegas
  • Patent number: 9107956
    Abstract: The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the small molecule drug not attached to the water-soluble oligomer.
    Type: Grant
    Filed: October 16, 2013
    Date of Patent: August 18, 2015
    Assignee: NEKTAR THERAPEUTICS
    Inventors: Jennifer Riggs-Sauthier, Lin Cheng, Tacey X. Viegas, Xuyuan Gu, Franco J. Duarte, Wen Zhang
  • Publication number: 20150197470
    Abstract: Methods of modifying the rate of systemic absorption of a drug administered to a subject by a pulmonary route, the method comprising covalently conjugating a hydrophilic polymer to a drug, wherein the drug has a half-life of elimination from the lung of less than about 180 minutes, to form a drug-polymer conjugate, wherein the drug-polymer conjugate has a net hydrophilic character and a weight average molecular weight of from about 50 to about 20,000 Daltons, and wherein the half-life of elimination from the lung of the drug-polymer conjugate is at least about 1.5-fold greater than the half-life of elimination from the lung of the drug, wherein the half-life of elimination from the lung is measured by bronchoalveolar lavage followed by assaying residual lung material.
    Type: Application
    Filed: April 8, 2014
    Publication date: July 16, 2015
    Applicant: Nektar Therapeutics
    Inventors: Michael D. BENTLEY, Tacey X. Viegas, Richard R. Goodin, Lin Cheng, Xuan Zhao
  • Publication number: 20150174264
    Abstract: The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the small molecule drug not attached to the water-soluble oligomer.
    Type: Application
    Filed: March 6, 2015
    Publication date: June 25, 2015
    Applicant: Nektar Therapeutics
    Inventors: Jennifer Riggs-Sauthier, Wen Zhang, Tacey X. Viegas, Michael D. Bentley
  • Publication number: 20140371258
    Abstract: Provided herein are water-soluble polymer conjugates of topotecan, along with compositions comprising the conjugates and related methods of making and using the same.
    Type: Application
    Filed: December 16, 2011
    Publication date: December 18, 2014
    Applicant: Nektar Therapeutics
    Inventors: Xuyuan Gu, Jennifer Riggs-Sauthier, Michael D. Bentley, Tacey X. Viegas
  • Publication number: 20140323514
    Abstract: Provided herein are water-soluble prodrugs, compositions comprising such prodrugs, and related methods of making and administering the same. The prodrugs of the invention comprise a water-soluble polymer having three or more arms, at least three of which are typically covalently attached to an active agent, e.g., a small molecule. The conjugates of the invention provide an optimal balance of polymer size and structure for achieving improved drug loading, since the conjugates of the invention possess three or more active agents releasably attached to a multi-armed water-soluble polymer. The prodrugs of the invention are therapeutically effective, and exhibit improved properties in-vivo when compared to unmodified parent drug.
    Type: Application
    Filed: July 3, 2014
    Publication date: October 30, 2014
    Inventors: Xuan Zhao, Michael David Bentley, Zhongxu Ren, Tacey X. Viegas
  • Publication number: 20140303403
    Abstract: Methods of modifying the rate of systemic absorption of a drug administered to a subject by a pulmonary route, the method comprising covalently conjugating a hydrophilic polymer to a drug, wherein the drug has a half-life of elimination from the lung of less than about 180 minutes, to form a drug-polymer conjugate, wherein the drug-polymer conjugate has a net hydrophilic character and a weight average molecular weight of from about 50 to about 20,000 Daltons, and wherein the half-life of elimination from the lung of the drug-polymer conjugate is at least about 1.5-fold greater than the half-life of elimination from the lung of the drug, wherein the half-life of elimination from the lung is measured by bronchoalveolar lavage followed by assaying residual lung material.
    Type: Application
    Filed: April 8, 2014
    Publication date: October 9, 2014
    Applicant: Nektar Therapeutics
    Inventors: Michael D. BENTLEY, Tacey X. Viegas, Richard R. Goodin, Lin Cheng, Xuan Zhao
  • Patent number: 8771662
    Abstract: Provided herein are water-soluble prodrugs, compositions comprising such prodrugs, and related methods of making and administering the same. The prodrugs of the invention comprise a water-soluble polymer having three or more arms, at least three of which are typically covalently attached to an active agent, e.g., a small molecule. The conjugates of the invention provide an optimal balance of polymer size and structure for achieving improved drug loading, since the conjugates of the invention possess three or more active agents releasably attached to a multi-armed water-soluble polymer. The prodrugs of the invention are therapeutically effective, and exhibit improved properties in-vivo when compared to unmodified parent drug.
    Type: Grant
    Filed: February 12, 2013
    Date of Patent: July 8, 2014
    Assignee: Nektar Therapeutics
    Inventors: Xuan Zhao, Michael David Bentley, Zhongxu Ren, Tacey X. Viegas
  • Publication number: 20140045770
    Abstract: The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the small molecule drug not attached to the water-soluble oligomer.
    Type: Application
    Filed: October 16, 2013
    Publication date: February 13, 2014
    Applicant: NEKTAR THERAPEUTICS
    Inventors: Jennifer RIGGS-SAUTHIER, Lin Cheng, Tacey X. Viegas, Xuyuan Gu, Franco J. Duarte, Wen Zhang
  • Patent number: 8598364
    Abstract: The invention provides protease inhibitors that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the protease inhibitors not attached to the water-soluble oligomer.
    Type: Grant
    Filed: March 12, 2008
    Date of Patent: December 3, 2013
    Assignee: Nektar Therapeutics
    Inventors: Jennifer Riggs-Sauthier, Lin Cheng, Tacey X. Viegas, Xuyuan Gu, Franco J. Duarte, Wen Zhang
  • Patent number: 8580919
    Abstract: Conjugates of a GLP-1 moiety may be covalently attached to one or more water-soluble polymers. For instance, a GLP-1 polymer conjugate may include a GLP-1 moiety releasably attached at its N-terminus to a water-soluble polymer. The GLP-1 polymer conjugate may include a GLP-1 moiety covalently attached to a water-soluble polymer, wherein the GLP-1 moiety possesses an N-methyl substituent.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: November 12, 2013
    Assignee: Nektar Therapeutics
    Inventors: Mary J. Bossard, Zhihao Fang, Tacey X. Viegas, Stewart A. Thompson, Mei-chang Kuo
  • Publication number: 20130096258
    Abstract: Conjugates of a GLP-1 moiety may be covalently attached to one or more water-soluble polymers. For instance, a GLP-1 polymer conjugate may include a GLP-1 moiety releasably attached at its N-terminus to a water-soluble polymer. The GLP-1 polymer conjugate may include a GLP-1 moiety covalently attached to a water-soluble polymer, wherein the GLP-1 moiety possesses an N-methyl substituent.
    Type: Application
    Filed: September 14, 2012
    Publication date: April 18, 2013
    Applicant: Nektar Therapeutics
    Inventors: Mary J. BOSSARD, Zhihao Fang, Tacey X. Viegas, Stewart A. Thompson, Mei-chang Kuo
  • Patent number: 8394365
    Abstract: Provided herein are water-soluble prodrugs, compositions comprising such prodrugs, and related methods of making and administering the same. The prodrugs of the invention comprise a water-soluble polymer having three or more arms, at least three of which are typically covalently attached to an active agent, e.g., a small molecule. The conjugates of the invention provide an optimal balance of polymer size and structure for achieving improved drug loading, since the conjugates of the invention possess three or more active agents releasably attached to a multi-armed water-soluble polymer. The prodrugs of the invention are therapeutically effective, and exhibit improved properties in-vivo when compared to unmodified parent drug.
    Type: Grant
    Filed: November 30, 2007
    Date of Patent: March 12, 2013
    Assignee: Nektar Therapeutics
    Inventors: Xuan Zhao, Michael David Bentley, Zhongxu Ren, Tacey X. Viegas
  • Publication number: 20130053400
    Abstract: The invention provides antihistamine drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the antihistamine drug not attached to the water-soluble oligomer.
    Type: Application
    Filed: September 7, 2012
    Publication date: February 28, 2013
    Applicant: Nektar Therapeutics
    Inventors: Jennifer Riggs-Sauthier, Wen Zhang, Tacey X. Viegas, Michael D. Bentley